Regulation
Alpha Tau concludes patient enrolment in ReSTART pivotal trial
Alpha Tau Medical has completed patient enrollment in its ReSTART pivotal trial, which evaluates Alpha DaRT for treating recurrent cutaneous squamous cell carcinoma (cSCC). The trial is a key milestone toward potential regulatory clearance of the device.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network